The bull market for the US health care industry will continue in 1995, except for small biotechnology companies which may undergo a merger-and-acquisition shakeout, according to Hambrecht & Quist analysts speaking at their 13th annual life sciences investment seminar last week in the USA.
This will be a good year for those investing in health services, medical devices, pharmaceuticals and large biotechnology stocks, they said, partly because the Republican Congressional majority is less likely to regulate the health care industry than the controlling Democrats.
The shift in politics has been profound, according to Larry Smith, managing director for life sciences research at H&Q, who noted the move from an anti-industry government, with people like John Dingell and Henry Waxman who firmly believed the American health care system was gouging the public, to the pro-industry outlook.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze